Members of the coronaviridae family are endemic to human populations and have caused
several epidemics and pandemics in recent history. In this review, we will discuss the …

Given the limitations of conventional invasive vaccines, such as the requirement for a cold
chain system and trained personnel, needle-based injuries, and limited immunogenicity …

A critical feature of the VSV vector platform is the ability to pseudotype the virus with different
glycoproteins from other viruses, thus altering cellular tropism of the recombinant virus. The …

Using our strongly immunogenic SmT1 SARS-CoV-2 spike antigen platform, we developed
antigens based on the Beta & Delta variants of concern (VOC). These antigens elicited …

Protein expression from stably transfected Chinese hamster ovary (CHO) clones is an
established but time‐consuming method for manufacturing therapeutic recombinant …

The virus-like particle (VLP) platform is a robust inducer of humoral and cellular immune
responses; hence, it has been used in vaccine development for several infectious diseases …

The nasal cavity is a primary checkpoint for the invasion of respiratory pathogens. Numerous
pathogens, including SARS-CoV-2, S. pneumoniae, S. aureus, etc., can adhere/colonize …

Mucosal vaccines have risen to prominence in the corona virus disease 2019 (COVID-19)
pandemic due to their ability to elicit both local antibody and tissue-resident T cell …

Targeting the site of infection is a promising strategy for improving vaccine effectivity. To
date, licensed COVID-19 vaccines have been administered intramuscularly despite the fact …

The emergency of new SARS-CoV-2 variants that feature increased immune escape marks
an urgent demand for better vaccines that will provide broader immunogenicity. Here, we …